Cargando…

Retrospective Analysis of Treatment-naive Slovenian Patients with Metastatic Melanoma Treated with Pembrolizumab – Real-world Experience

BACKGROUND: Based on recent data from clinical trials, the immune checkpoint inhibitor pembrolizumab prolongs survival and has a good toxicity profile in patients with advanced or metastatic melanoma. However, the question remains whether these results are transmitted into daily clinical practice. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hribernik, Nezka, Boc, Marko, Ocvirk, Janja, Knez-Arbeiter, Jasna, Mesti, Tanja, Ignjatovic, Marija, Rebersek, Martina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sciendo 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087416/ https://www.ncbi.nlm.nih.gov/pubmed/31955148 http://dx.doi.org/10.2478/raon-2020-0003

Ejemplares similares

Molecular Biomarkers and Histological Parameters Impact on Survival and Response to First- Line Systemic Therapy of Metastatic Colorectal Cancer Patients
por: Rebersek, Martina, et al.
Publicado: (2019)

Prevalence of BRAF, NRAS and c-KIT Mutations in Slovenian Patients with Advanced Melanoma
por: Moltara, Maja Ebert, et al.
Publicado: (2018)

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
por: Mesti, Tanja, et al.
Publicado: (2015)

Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience
por: Ocvirk, Janja, et al.
Publicado: (2016)

The Five-year KRAS, NRAS and BRAF Analysis Results and Treatment Patterns in Daily Clinical Practice in Slovenia in 1(st) Line Treatment of Metastatic Colorectal (mCRC) Patients with RAS Wild-type Tumour (wtRAS) – A Real- Life Data Report 2013–2018
por: Mesti, Tanja, et al.
Publicado: (2023)

Adverse Events During Immunotherapy in Slovenian Patients with Metastatic Melanoma Reveal a Positive Correlation with Better Treatment Outcomes
por: Mesti, Tanja, et al.
Publicado: (2021)

Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors
por: Mesti, Tanja, et al.
Publicado: (2023)

Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer – a single institution retrospective analysis
por: Rebersek, Martina, et al.
Publicado: (2011)

Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study
por: Hribernik, Nežka, et al.
Publicado: (2021)

Malignant gliomas: old and new systemic treatment approaches
por: Mesti, Tanja, et al.
Publicado: (2016)

The Prognostic and Predictive Value of Human Gastrointestinal Microbiome and Exosomal mRNA Expression of PD-L1 and IFNγ for Immune Checkpoint Inhibitors Response in Metastatic Melanoma Patients: PROTOCOL TRIAL
por: Erman, Ana, et al.
Publicado: (2023)

Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia
por: Mesti, Tanja, et al.
Publicado: (2022)

The cost of systemic therapy for metastatic colorectal carcinoma in Slovenia: discrepancy analysis between cost and reimbursement
por: Mesti, Tanja, et al.
Publicado: (2015)

Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial
por: Skof, Erik, et al.
Publicado: (2009)

Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib
por: Gavric, Ana Ursula, et al.
Publicado: (2018)

Idiopathic Pulmonary Fibrosis in Patients with Early-stage Non-small-cell Lung Cancer after Surgical Resection
por: Nezka, Hribernik, et al.
Publicado: (2019)

Metabolic Impact of Anti-Angiogenic Agents on U87 Glioma Cells
por: Mesti, Tanja, et al.
Publicado: (2014)

Choroidal thickening with serous retinal detachment in BRAF/MEK inhibitor-induced uveitis: A case report
por: Kiraly, Peter, et al.
Publicado: (2022)

Prevalence of variations in melanoma susceptibility genes among Slovenian melanoma families
por: Peric, Barbara, et al.
Publicado: (2008)

Pembrolizumab: First in Class for Treatment of Metastatic Melanoma
por: Barnhart, Carrie
Publicado: (2015)

Pembrolizumab and tavokinogene telseplasmid electroporation in metastatic melanoma
por: Dollin, Yonatan, et al.
Publicado: (2020)

Combination of Pembrolizumab with Electrochemotherapy in Cutaneous Metastases from Melanoma: A Comparative Retrospective Study from the InspECT and Slovenian Cancer Registry
por: Campana, Luca G., et al.
Publicado: (2021)

Treatment of osteoporosis with teriparatide: The Slovenian experience
por: Kocjan, Tomaz, et al.
Publicado: (2021)

Pembrolizumab as first-line treatment for metastatic uveal melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Disseminated blastomycosis in a patient on pembrolizumab for metastatic melanoma
por: Ferguson, Ian, et al.
Publicado: (2019)

Tumoral Melanosis Associated with Pembrolizumab-Treated Metastatic Melanoma
por: Bari, Omar, et al.
Publicado: (2017)

Nuclear Magnetic Resonance Metabolic Fingerprint of Bevacizumab in Mutant IDH1 Glioma Cells
por: Mesti, Tanja, et al.
Publicado: (2018)

Lichen planopilaris associated with pembrolizumab in a patient with metastatic melanoma
por: Cogen, Anna L., et al.
Publicado: (2018)

Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis
por: Zhang, Qi, et al.
Publicado: (2020)

Management of cetuximab-induced skin toxicity with the prophylactic use of topical vitamin K1 cream
por: Ocvirk, Janja
Publicado: (2010)

Consensus Molecular Subtypes (CMS) in Metastatic Colorectal Cancer - Personalized Medicine Decision
por: Rebersek, Martina
Publicado: (2020)

Genetic Characteristics and Long-Term Follow-Up of Slovenian Patients with RPGR Retinal Dystrophy
por: Hadalin, Vlasta, et al.
Publicado: (2023)

Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
por: Tsur, Neta, et al.
Publicado: (2019)

Durable Response with Single-Agent Pembrolizumab in a Patient with Metastatic Melanoma
por: Cyriac, Sanju, et al.
Publicado: (2021)

Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid
por: Beck, Kristen M., et al.
Publicado: (2016)

AIHA and Pancytopenia as Complications of Pembrolizumab Therapy for Metastatic Melanoma: A Case Report
por: Ni, Dan, et al.
Publicado: (2019)

The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
por: Ny, Lars, et al.
Publicado: (2021)

Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers
por: Navani, Vishal, et al.
Publicado: (2021)

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
por: Shaikh, Saba S., et al.
Publicado: (2022)

Quantitative Risk Assessment of Exposure to Mycobacterium avium subsp. paratuberculosis (MAP) via Different Types of Milk for the Slovenian Consumer
por: Knific, Tanja, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tolke6i9iovho0vbjcspfcmo0t